Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

Summary by stocktitan.net
Royalty Pharma will now collect a tiered 8–16% cut of Evrysdi sales, paying $240M plus up to $60M milestones, with higher rates starting from Q1 2026.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi

·United States
Read Full Article
stocktitan.netstocktitan.net

A $1.9B spinal atrophy drug’s royalties just found a new owner

Royalty Pharma will now collect a tiered 8–16% cut of Evrysdi sales, paying $240M plus up to $60M milestones, with higher rates starting from Q1 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, December 29, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Basel icon

Basel

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal